Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2016 Oct 7;15(12):2863–2874. doi: 10.1158/1535-7163.MCT-16-0515

Figure 1. Effect of fisetin, cabazitaxel and their combination in-vitro.

Figure 1

Representative histogram images of PCa cells showing cell viability assessed by MTT assay with fisetin (20 μM), cabazitaxel (5nM) and the combination (fisetin 20 μM and cabazitaxel 5nM). A. PrEC cells. B. 22Rν1cells. C. PC-3M-luc-6 cells. D. C4-2 cells. E. Representative photograph showing the effect of fisetin (20μM) and cabazitaxel (5nM) treatment on growth of PC-3 cells investigated by monolayer colony formation assay. Data are shown as a mean ± SD of at least three independent experiments performed in triplicate; ***, p ≤ 0.002; NS = not significant.